Treace to Report Fourth Quarter and Full-Year 2023 Financial Results
07 Febrero 2024 - 3:05PM
Treace Medical Concepts, Inc. (“Treace” or the “Company”)
(NasdaqGS: TMCI), a medical technology company driving a
fundamental shift in the surgical treatment of bunions and related
midfoot deformities through its flagship Lapiplasty® and
Adductoplasty® Procedures, today announced that it will release
financial results for the fourth quarter and full year of 2023
after the close of trading on Tuesday, February 27, 2024. Company
management will host a conference call to discuss financial results
beginning at 4:30 pm ET.
Investors interested in listening to the
conference call may do so by registering. Once registered,
participants will receive dial-in numbers and a unique pin to join
the call and ask questions. A live and archived webcast of the
event and investor presentation will be available on the Company’s
investor relations website at https://investors.treace.com/.
Internet Posting of
Information
Treace routinely posts information that may be
important to investors in the “Investor Relations” section of its
website at www.treace.com. The Company encourages investors and
potential investors to consult the Treace website regularly for
important information about Treace.
About Treace Medical
Concepts
Treace Medical Concepts, Inc. is a medical
technology company with the goal of advancing the standard of care
for the surgical management of bunion and related midfoot
deformities. Bunions are complex 3-dimensional deformities that
originate from an unstable joint in the middle of the foot and
affect approximately 67 million Americans, of which Treace
estimates 1.1 million are annual surgical candidates. Treace has
pioneered and patented the Lapiplasty® 3D Bunion
Correction® System – a combination of instruments, implants,
and surgical methods designed to surgically correct all 3 planes of
the bunion deformity and secure the unstable joint, addressing the
root cause of the bunion and helping patients get back to their
active lifestyles. To further support the needs of bunion patients,
Treace has introduced its Adductoplasty® Midfoot Correction
System, designed for reproducible surgical correction of the
midfoot as well as its Hammertoe PEEK Fixation System designed to
address hammertoe, claw toe and mallet toe deformities. The company
continues to expand its footprint in the foot and ankle market with
the introduction of its SpeedPlate™ Rapid Compression
Implants, an innovative fixation platform with broad versatility
across Lapiplasty® and Adductoplasty® procedures, as well
as other common bone fusion procedures of the foot. For more
information, please visit www.treace.com.
To learn more about Treace, connect with us on
LinkedIn, Twitter, Facebook and Instagram.
Contacts:
Treace Medical Concepts,
Inc.Julie Dewey, IRCChief Communications & Investor
Relations Officerjddewey@treace.com | 209-613-6945
Treace Medical Concepts (NASDAQ:TMCI)
Gráfica de Acción Histórica
De Ago 2024 a Sep 2024
Treace Medical Concepts (NASDAQ:TMCI)
Gráfica de Acción Histórica
De Sep 2023 a Sep 2024